GlassScriptPhysician profile
Matthew Lawrence Nettleton
NPI 1114983616
$3,381.25
in general payments reported to CMS, 2019-2025
29 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.51 · 2020: $14.23 · 2021: $199 · 2022: $362 · 2023: $639 · 2024: $886 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,760 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,759.78 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,225.59 | 2021-2025 | |
| Dexcom, INC. | $338.81 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Phathom Pharmaceuticals, INC. | $296.03 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $242.44 | 2020-2023 | Xarelto |
| Pfizer INC. | $152.90 | 2023-2025 | |
| Exact Sciences Corporation | $131.77 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $109.75 | 2022-2025 | Mounjaro, Zepbound |
| Cequr Corporation | $100.00 | 2022 | |
| Smith+Nephew, INC. | $91.96 | 2023 | Stravix |
| Astrazeneca Pharmaceuticals LP | $75.73 | 2023-2025 | Farxiga |
| Novo Nordisk INC | $62.79 | 2021-2025 | Rybelsus, Wegovy |
| Amgen INC. | $61.81 | 2024-2025 | Repatha, Otezla, Evenity |
| Insulet Corporation | $58.61 | 2021-2024 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.58 | 2024-2025 | Xifaxan |
| Abbott Laboratories | $44.68 | 2023-2025 | Proclaim, Freestyle Libre 3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.23 | 2019-2025 | Jardiance |
| Ardelyx, INC. | $36.64 | 2025 | Ibsrela |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.98 | 2023 | Lifevest |
| Astellas Pharma US INC | $33.79 | 2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $33.72 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $27.84 | 2024-2025 | Onzetra Xsail, Contrave |
| Merck Sharp & Dohme LLC | $21.25 | 2022 | |
| Allergan, INC. | $19.93 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $19.16 | 2021 | |
| Beta Bionics, INC. | $16.12 | 2024 | Ilet Bionic Pancreas |
| Hologic Sales and Service, LLC | $15.67 | 2023 | Aptima, Thinprep 2000 Processor |
| Tactile Systems Technology INC | $14.17 | 2025 | Nimbl, Flexitouch Plus |
| Glaxosmithkline, LLC. | $13.51 | 2024 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Nettleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.